<DOC>
	<DOCNO>NCT00002504</DOCNO>
	<brief_summary>RATIONALE : Interleukin-2 may stimulate person 's white blood cell kill metastatic cancer cell . Interferon alfa may interfere growth cancer cell . Combining interleukin-2 interferon alfa may kill cancer cell . PURPOSE : Phase II trial study effectiveness interleukin-2 plus interferon alfa treat adult metastatic cancer .</brief_summary>
	<brief_title>Interleukin-2 Plus Interferon Alfa Treating Adults With Metastatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate , failure-free survival , overall survival interleukin-2 interferon alpha administer subcutaneously outpatient basis 8 week patient metastatic cancer . II . Determine toxicity associate therapy . OUTLINE : Biological Response Modifier Therapy . Interleukin-2 ( Cetus ) , IL-2 , NSC-373364 ; Interferon alpha ( Schering ) , IFN-A , NSC-377523 . PROJECTED ACCRUAL : Up 30 patient various malignancy enter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic cancer type Measurable evaluable disease require , i.e . : Bidimensionally measurable lesion physical exam , xray , CT , MRI , radiologic procedure Any lesion apparent radiologic exam measurable 2 perpendicular diameter Previously irradiate lesion acceptable provide subsequent progression document No active brain metastasis Previously treat brain metastasis allow provide measurable/evaluable disease exists outside CNS PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Hematopoietic : ( within 14 day prior entry ) WBC least 3,000 Platelets least 100,000 Hematocrit least 30 % ( may transfuse ) Hepatic : ( within 14 day prior entry ) Bilirubin le 2.0 mg/dl PT PTT normal Renal : ( within 14 day prior entry ) Creatinine le 2.0 mg/dl Cardiovascular : No MI within 6 month No medication arrhythmia No medication CHF Hypertension stable medication allow Pulmonary : pO2 least 60 mm Hg patient primary lung cancer symptomatic pulmonary disease Reasonable respiratory reserve No dyspnea rest No requirement supplemental oxygen Other : No familial history malignant hyperthermia No chronic underlie immunodeficiency disease No HIV seropositivity No active infection require antibiotic therapy No serious intercurrent illness No concurrent malignancy No pregnant nursing woman Adequate contraception require fertile woman PRIOR CONCURRENT THERAPY : No concurrent therapy anticancer agents No concurrent immunosuppressive agent ( e.g. , cyclosporin ) Biologic therapy : Prior interferon alpha allow Chemotherapy : At least 4 week since systemic chemotherapy recovery require Endocrine therapy : No concurrent corticosteroid Radiotherapy : At least 4 week since radiotherapy Surgery : Adequate recovery require Other : No prior organ allograft</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>meningeal chronic myelogenous leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>untreated hairy cell leukemia</keyword>
	<keyword>progressive hairy cell leukemia , initial treatment</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>